Advertisement

Organisation › Details
Sarah Cannon Research Institute
Sarah Cannon Research Institute is the research arm of HCA’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials throughout the United States and United Kingdom. Sarah Cannon’s network of strategic sites includes more than 275 physicians who engage in research. The organization has led more than 220 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in more than two-thirds of approved cancer therapies over the last 10 years. Additionally, Sarah Cannon offers drug development research support services for industry sponsors as well as strategic investigator’s through its contract research organization (CRO), Sarah Cannon Development Innovations (formerly known as SCRI Development Innovations). As the CRO of Sarah Cannon, it leverages expert physician leadership to design and implement clinical trials that effectively and efficiently lead to rapid clinical development decisions. *
![]() |
Start | 2016-09-29 existent |
Group | Hospital Corporation of America (HCA) (Group) | |
![]() |
Industry | oncology |
Industry 2 | cancer immunotherapy (immuno-oncology, I-O) | |
City | n. a. Nashville, TN | |
Address record changed: 2016-10-03 | ||
Basic data | Employees | n. a. |
* Document for �About Section�: Boehringer Ingelheim. (9/29/16). "Press Release: Boehringer Ingelheim and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Immune-oncology Therapies". Ingelheim. | ||
Record changed: 2019-07-13 |
Advertisement
![Picture [LSA] Life-Sciences-Asia.com – The Business Web Portal 650x89px](/banner/iito-20190621-650-089-life-sciences-asia.jpg)
More documents for Hospital Corporation of America (HCA) (Group)
- [1] Boehringer Ingelheim. (10/30/17). "Press Release: Boehringer Ingelheim Expands Collaboration with Sarah Cannon Research Institute to Investigate Novel Immuno-oncology Combination Therapy". Ingelheim & Nashville, TN....
- [2] Autolus Therapeutics Ltd.. (9/18/17). "Press Release: Autolus Announces First-Dose Cohort Completed in APRIL Study of AUTO2. A Phase I/II Study in Patients with Multiple Myeloma"....
- [3] Boehringer Ingelheim. (9/29/16). "Press Release: Boehringer Ingelheim and Sarah Cannon Research Institute Launch Strategic Collaboration to Develop Novel Immune-oncology Therapies". Ingelheim....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
Advertisement

» top